Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has been invited to present at the 9th Annual Gateway Conference, which is being held virtually on September 9-10, 2020.

Plus Therapeutics, Inc. management is scheduled to present on Thursday, September 10 at 3.30 p.m. eastern time, with one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2492/37150.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email conference@gatewayir.com.

About the Gateway Conference The 9th Annual Gateway Conference is an invite-only conference presented by Gateway Investor Relations, a full-service financial communications firm. The conference was created to bring together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features a long list of companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. Follow the Gateway Conference on Twitter and join the conversation using the #GatewayIRConference hashtag. For more information, visit gatewayir.com/conference.

About Plus Therapeutics, Inc.Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at plustherapeutics.com and respect-trials.com.

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company’s potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company’s potential to develop drug candidates currently in its product pipeline; and the Company’s potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA’s accelerated regulatory pathways; and the risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Contact:Plus Therapeutics, Inc.  Andrew Sims VP – Chief Financial Officer, Investor Relations Phone: +1.619.333.4150 Email: ir@plustherapeutics.com Corporate Website: plustherapeutics.comClinical Website: respect-trials.com

Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Plus Therapeutics Charts.
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Plus Therapeutics Charts.